Skip to main content
Clinical Trials/NCT04598802
NCT04598802
Completed
N/A

A Physician-initiated, Multicentre, Ambispective, Observational Registry of Patients Undergoing Complex Aortic Procedures With the Use of the Bard Covera Plus (Tempe, Arizona, USA) Covered Self-expandable Stents

IRCCS San Raffaele33 sites in 2 countries300 target enrollmentOctober 16, 2020
ConditionsAneurysm

Overview

Phase
N/A
Intervention
Not specified
Conditions
Aneurysm
Sponsor
IRCCS San Raffaele
Enrollment
300
Locations
33
Primary Endpoint
technical success
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of the registry is to evaluate the peri-operative and short-, mid- and long-term outcomes of the Bard Covera Plus (Tempe, Arizona, USA) for the treatment of atherosclerotic aorto-iliac aneurysm in combination with a multibranched endograft

Registry
clinicaltrials.gov
Start Date
October 16, 2020
End Date
October 30, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Bertoglio Luca

Principal Investigator

IRCCS San Raffaele

Eligibility Criteria

Inclusion Criteria

  • Adult patients ≥18 years
  • Patients who underwent/will undergo a complex aortic procedure with the use of a Covera Plus covered stent graft as a bridging stent, in the centres involved in this Registry
  • Subject has consented for study participation and signed the approved Informed Consent

Exclusion Criteria

  • Bleeding diathesis or coagulopathy
  • Patients with active systemic or cutaneous infection or inflammation
  • Patients who are pregnant or lactating
  • Patient younger than 18 years of age
  • Patients who did not receive treatment using a Covera Plus covered stent graft.

Outcomes

Primary Outcomes

technical success

Time Frame: 30 days

freedom from type I or type III endoleak, stenosis/occlusion, dislocation/kinking

Branch instability

Time Frame: 30 days

freedom from branch-related complications

Primary clinical success

Time Frame: 30 days

freedom from death, type I/III endoleak, graft infection/thrombosis, aneurysm expansion and/or rupture, conversion to open repair, or new treatment-related thoraco-abdominal pathologies

Study Sites (33)

Loading locations...

Similar Trials